Led by Liang Chen from the Department of Liver Disease at the Shanghai Public Health Clinical Center, Fudan University, Shanghai, China, the research team sought to identify the key risk factors for pulmonary infections in HBV-ACLF patients, assess how these infections impact patient outcomes, and develop a reliable prognostic model for early intervention.
To achieve these goals, the researchers retrospectively analyzed the clinical data of 393 HBV-ACLF patients. Using logistic regression, they identified risk factors associated with pulmonary infection. They evaluated the factors influencing prognosis in infected patients. They also developed a prognostic prediction model using the Nomogram method.
The key findings of the study include the following:
- Pulmonary Infections in HBV-ACLF Patients: Pulmonary infections were present in 38.7% of patients with HBV-ACLF.
- Impact on Mortality: Patients with pulmonary infections experienced significantly higher short-term mortality compared to those without infections (65.71% vs. 35.02%).
- Risk Factors for Pulmonary Infection: Independent risk factors for pulmonary infections included total bilirubin (TBIL), C-reactive protein (CRP), invasive procedures, peritoneal effusion, and hepatic encephalopathy.
- 30-day Mortality Risk Factors: Creatinine, international normalized ratio (INR), comorbid diabetes mellitus, neutrophil counts, and lymphocyte counts were identified as independent factors influencing 30-day mortality in patients with pulmonary infections.
- Predictive Model: The new predictive model, incorporating the identified risk factors, achieved an AUC of 0.832, outperforming traditional prognostic models like CTP, MELD, and MELD-Na.
The authors concluded, “Patients with HBV-ACLF are highly vulnerable to pulmonary infections, particularly fungal infections, which are linked to poorer outcomes. Given the diverse clinical presentations, timely identification of risk factors, careful evaluation of prognosis, and judicious use of antibiotics based on etiological findings are essential for guiding early and effective intervention.”
This study highlights the critical need for early identification and management of pulmonary infections in HBV-ACLF patients. By utilizing the new predictive model, healthcare providers can better assess risk, intervene promptly, and ultimately improve patient outcomes in this high-risk population.
Reference:
Wang, N., Zheng, Y., Tao, S. et al. Risk factors and prognosis of pulmonary infection in hepatitis B-related acute-on-chronic liver failure: a retrospective cohort study. BMC Pulm Med 25, 178 (2025). https://doi.org/10.1186/s12890-025-03628-7
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.